{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T04:16:38Z","timestamp":1772770598732,"version":"3.50.1"},"publisher-location":"Berlin, Heidelberg","reference-count":25,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"value":"9783662474662","type":"print"},{"value":"9783662474679","type":"electronic"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2015]]},"DOI":"10.1007\/8904_2015_422","type":"book-chapter","created":{"date-parts":[[2015,3,30]],"date-time":"2015-03-30T22:57:44Z","timestamp":1427756264000},"page":"7-15","source":"Crossref","is-referenced-by-count":9,"title":["Effect and Tolerability of Agalsidase Alfa in Patients with Fabry Disease Who Were Treatment Na\u00efve or Formerly Treated with Agalsidase Beta or Agalsidase Alfa"],"prefix":"10.1007","author":[{"given":"Ozlem","family":"Goker-Alpan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Khan","family":"Nedd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suma P.","family":"Shankar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yeong-Hau H.","family":"Lien","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Neal","family":"Weinreb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Wijatyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Chang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rick","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2015,3,31]]},"reference":[{"key":"422_CR1","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s10545-014-9717-4","volume":"37","author":"LJ Anderson","year":"2014","unstructured":"Anderson LJ, Wyatt KM, Henley W et al (2014) Long-term effectiveness of enzyme replacement therapy in Fabry disease: results from the NCS-LSD cohort study. J Inherit Metab Dis 37:969\u2013978","journal-title":"J Inherit Metab Dis"},{"key":"422_CR2","doi-asserted-by":"publisher","first-page":"77","DOI":"10.7326\/0003-4819-146-2-200701160-00148","volume":"146","author":"M Banikazemi","year":"2007","unstructured":"Banikazemi M, Bultas J, Waldek S et al (2007) Agalsidase-beta therapy for advanced Fabry disease: a randomized trial. Ann Intern Med 146:77\u201386","journal-title":"Ann Intern Med"},{"key":"422_CR3","doi-asserted-by":"publisher","first-page":"838","DOI":"10.1111\/j.1365-2362.2004.01424.x","volume":"34","author":"M Beck","year":"2004","unstructured":"Beck M, Ricci R, Widmer U et al (2004) Fabry disease: overall effects of agalsidase alfa treatment. Eur J Clin Invest 34:838\u2013844","journal-title":"Eur J Clin Invest"},{"key":"422_CR4","doi-asserted-by":"publisher","first-page":"243","DOI":"10.3346\/jkms.2008.23.2.243","volume":"23","author":"JH Choi","year":"2008","unstructured":"Choi JH, Cho YM, Suh KS et al (2008) Short-term efficacy of enzyme replacement therapy in Korean patients with Fabry disease. J Korean Med Sci 23:243\u2013250","journal-title":"J Korean Med Sci"},{"key":"422_CR5","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1136\/adc.51.11.875","volume":"51","author":"R Counahan","year":"1976","unstructured":"Counahan R, Chantler C, Ghazali S, Kirkwood B, Rose F, Barratt TM (1976) Estimation of glomerular filtration rate from plasma creatinine concentration in children. Arch Dis Child 51:875\u2013878","journal-title":"Arch Dis Child"},{"key":"422_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1111\/j.1651-2227.2003.tb00214.x","volume":"92","author":"F Dehout","year":"2003","unstructured":"Dehout F, Schwarting A, Beck M et al (2003) Effects of enzyme replacement therapy with agalsidase alfa on glomerular filtration rate in patients with Fabry disease: preliminary data. Acta Paediatr Suppl 92:14\u201315, discussion 15","journal-title":"Acta Paediatr Suppl"},{"key":"422_CR7","unstructured":"European Medicines Agency (2014) Replagal Summary of Product Characteristics. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000369\/WC500053612.pdf . Accessed 7 July 2014"},{"key":"422_CR8","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1681\/ASN.2006080816","volume":"18","author":"DP Germain","year":"2007","unstructured":"Germain DP, Waldek S, Banikazemi M et al (2007) Sustained, long-term renal stabilization after 54 months of agalsidase beta therapy in patients with Fabry disease. J Am Soc Nephrol 18:1547\u20131557","journal-title":"J Am Soc Nephrol"},{"key":"422_CR9","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.ijcard.2008.03.007","volume":"130","author":"C Kampmann","year":"2008","unstructured":"Kampmann C, Linhart A, Baehner F et al (2008) Onset and progression of the Anderson-Fabry disease related cardiomyopathy. Int J Cardiol 130:367\u2013373","journal-title":"Int J Cardiol"},{"key":"422_CR10","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1007\/BF03261891","volume":"26","author":"GM Keating","year":"2012","unstructured":"Keating GM (2012) Agalsidase alfa: a review of its use in the management of Fabry disease. BioDrugs 26:335\u2013354","journal-title":"BioDrugs"},{"key":"422_CR11","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1515\/CCLM.2010.048","volume":"48","author":"R Kr\u00fcger","year":"2010","unstructured":"Kr\u00fcger R, Bruns K, Grunhage S et al (2010) Determination of globotriaosylceramide in plasma and urine by mass spectrometry. Clin Chem Lab Med 48:189\u2013198","journal-title":"Clin Chem Lab Med"},{"key":"422_CR12","first-page":"128","volume":"883\u2013884","author":"R Kr\u00fcger","year":"2011","unstructured":"Kr\u00fcger R, Tholey A, Jakoby T et al (2011) Quantification of the Fabry marker lysoGb3 in human plasma by tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 883\u2013884:128\u2013135","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"422_CR13","doi-asserted-by":"publisher","first-page":"137","DOI":"10.7326\/0003-4819-139-2-200307150-00013","volume":"139","author":"AS Levey","year":"2003","unstructured":"Levey AS, Coresh J, Balk E et al (2003) National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Ann Intern Med 139:137\u2013147","journal-title":"Ann Intern Med"},{"key":"422_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.7326\/0003-4819-145-4-200608150-00004","volume":"145","author":"AS Levey","year":"2006","unstructured":"Levey AS, Coresh J, Greene T et al (2006) Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med 145:247\u2013254","journal-title":"Ann Intern Med"},{"key":"422_CR15","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1111\/j.1523-1755.2004.00924.x","volume":"66","author":"GE Linthorst","year":"2004","unstructured":"Linthorst GE, Hollak CE, Donker-Koopman WE, Strijland A, Aerts JM (2004) Enzyme therapy for Fabry disease: neutralizing antibodies toward agalsidase alpha and beta. Kidney Int 66:1589\u20131595","journal-title":"Kidney Int"},{"key":"422_CR16","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1136\/jmg.38.11.769","volume":"38","author":"KD MacDermot","year":"2001","unstructured":"MacDermot KD, Holmes A, Miners AH (2001) Anderson-Fabry disease: clinical manifestations and impact of disease in a cohort of 60 obligate carrier females. J Med Genet 38:769\u2013775","journal-title":"J Med Genet"},{"key":"422_CR17","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1007\/s00125-009-1268-0","volume":"52","author":"GM Magee","year":"2009","unstructured":"Magee GM, Bilous RW, Cardwell CR, Hunter SJ, Kee F, Fogarty DG (2009) Is hyperfiltration associated with the future risk of developing diabetic nephropathy? A meta-analysis. Diabetologia 52:691\u2013697","journal-title":"Diabetologia"},{"key":"422_CR18","doi-asserted-by":"publisher","first-page":"1986","DOI":"10.1016\/S0140-6736(09)61493-8","volume":"374","author":"A Mehta","year":"2009","unstructured":"Mehta A, Beck M, Elliott P et al (2009) Enzyme replacement therapy with agalsidase alfa in patients with Fabry\u2019s disease: an analysis of registry data. Lancet 374:1986\u20131996","journal-title":"Lancet"},{"key":"422_CR19","doi-asserted-by":"publisher","first-page":"e47805","DOI":"10.1371\/journal.pone.0047805","volume":"7","author":"SM Rombach","year":"2012","unstructured":"Rombach SM, Aerts JM, Poorthuis BJ et al (2012) Long-term effect of antibodies against infused alpha-galactosidase A in Fabry disease on plasma and urinary (lyso)Gb3 reduction and treatment outcome. PLoS One 7:e47805","journal-title":"PLoS One"},{"key":"422_CR20","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1186\/1750-1172-8-47","volume":"8","author":"SM Rombach","year":"2013","unstructured":"Rombach SM, Smid BE, Bouwman MG, Linthorst GE, Dijkgraaf MG, Hollak CE (2013) Long term enzyme replacement therapy for Fabry disease: effectiveness on kidney, heart and brain. Orphanet J Rare Dis 8:47","journal-title":"Orphanet J Rare Dis"},{"key":"422_CR21","doi-asserted-by":"publisher","first-page":"2743","DOI":"10.1001\/jama.285.21.2743","volume":"285","author":"R Schiffmann","year":"2001","unstructured":"Schiffmann R, Kopp JB, Austin HA 3rd et al (2001) Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 285:2743\u20132749","journal-title":"JAMA"},{"key":"422_CR22","first-page":"77","volume":"66","author":"A Schwarting","year":"2006","unstructured":"Schwarting A, Dehout F, Feriozzi S et al (2006) Enzyme replacement therapy and renal function in 201 patients with Fabry disease. Clin Nephrol 66:77\u201384","journal-title":"Clin Nephrol"},{"key":"422_CR23","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/1750-1172-6-69","volume":"6","author":"BE Smid","year":"2011","unstructured":"Smid BE, Rombach SM, Aerts JM et al (2011) Consequences of a global enzyme shortage of agalsidase beta in adult Dutch Fabry patients. Orphanet J Rare Dis 6:69. doi: 10.1186\/1750-1172-1186-1169","journal-title":"Orphanet J Rare Dis"},{"key":"422_CR24","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1111\/joim.12077","volume":"274","author":"F Weidemann","year":"2013","unstructured":"Weidemann F, Niemann M, Stork S et al (2013) Long-term outcome of enzyme-replacement therapy in advanced Fabry disease: evidence for disease progression towards serious complications. J Intern Med 274:331\u2013341","journal-title":"J Intern Med"},{"key":"422_CR25","doi-asserted-by":"publisher","first-page":"1132","DOI":"10.1681\/ASN.2008080870","volume":"20","author":"M West","year":"2009","unstructured":"West M, Nicholls K, Mehta A et al (2009) Agalsidase alfa and kidney dysfunction in Fabry disease. J Am Soc Nephrol 20:1132\u20131139","journal-title":"J Am Soc Nephrol"}],"container-title":["JIMD Reports","JIMD Reports, Volume 23"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/8904_2015_422","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,9]],"date-time":"2023-08-09T02:47:17Z","timestamp":1691549237000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/8904_2015_422"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"ISBN":["9783662474662","9783662474679"],"references-count":25,"URL":"https:\/\/doi.org\/10.1007\/8904_2015_422","relation":{},"ISSN":["2192-8304","2192-8312"],"issn-type":[{"value":"2192-8304","type":"print"},{"value":"2192-8312","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}